title: Effects of angiotensin-converting enzyme inhibition on renal sodium handling after furosemide injection.
abstract: The goal of this study was to quantitate the effect of angiotensin-converting enzyme inhibition on renal sodium handling after furosemide injection. The study was carried out on low and normal salt intake to assess potential interaction with salt balance. Eighteen healthy normotensive volunteers were examined in a double placebo-controlled parallel group design. Subjects were randomly put on either low-salt (20 mmol/day) or normal-salt (110 mmol/day) diet. In either arm of the diet volunteers were first treated orally with placebo for 1 week and subsequently with 2.5 mg/day of the angiotensin-converting enzyme inhibitor cilazapril for another 1 week. Cumulative 24-h urinary sodium excretion was measured on the 6th day of the respective week after sham injection and on the 7th day after injection of 40 mg furosemide. Compared to pretreatment with placebo, pretreatment with cilazapril resulted in a higher cumulative sodium excretion after furosemide injection (day 7) than after the sham injection (day 6) on both salt intakes. The difference in natriuresis (cilazapril versus placebo) was evident 2 and 3 h after injection of furosemide. Neither the time of onset nor the magnitude of antinatriuresis were affected by cilazapril. Following furosemide angiotensin II increased significantly even after cilazapril pretreatment. Cilazapril tended to reduce urinary furosemide excretion. At any given urinary furosemide concentration, the increment in urinary sodium excretion was significantly greater with cilazapril irrespective of salt intake. The study shows that (a) cilazapril increases furosemide-induced natriuresis irrespective of salt intake, (b) antinatriuresis is not affected by cilazapril, and (c) angiotensin II levels rise after furosemide on cilazapril in therapeutic doses.
authors.affiliation: Medizinische Klinik, Klinikum der Universität Heidelberg.
authors.forename: R
authors.initials: R
authors.lastname: Nowack
authors.forename: D
authors.initials: D
authors.lastname: Fliser
authors.forename: J
authors.initials: J
authors.lastname: Richter
authors.forename: C
authors.initials: C
authors.lastname: Horne
authors.forename: E
authors.initials: E
authors.lastname: Mutschler
authors.forename: E
authors.initials: E
authors.lastname: Ritz
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D017315:Cilazapril / Q000494:pharmacology*; D005665:Furosemide / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects*; D008297:Male; D009318:Natriuresis / Q000187:drug effects*; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D012016:Reference Values; D012982:Sodium, Dietary / Q000008:administration & dosage
chemical_list: D012982:Sodium, Dietary; D000804:Angiotensin II; D017315:Cilazapril; D000450:Aldosterone; D005665:Furosemide; D007703:Peptidyl-Dipeptidase A